Free Trial
NYSEAMERICAN:ARMP

Armata Pharmaceuticals 8/14/2023 Earnings Report

Armata Pharmaceuticals logo
$1.44 +0.09 (+6.85%)
Closing price 05/2/2025 04:10 PM Eastern
Extended Trading
$1.45 +0.01 (+0.90%)
As of 05/2/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Armata Pharmaceuticals EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.35
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Armata Pharmaceuticals Revenue Results

Actual Revenue
$0.98 million
Expected Revenue
$1.50 million
Beat/Miss
Missed by -$520.00 thousand
YoY Revenue Growth
N/A

Armata Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Armata Pharmaceuticals' next earnings date is estimated for Tuesday, May 6, 2025, based on past reporting schedules.

Conference Call Resources

Armata Pharmaceuticals Earnings Headlines

Armata Pharmaceuticals secures additional DoD funding
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year
See More Armata Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Armata Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Armata Pharmaceuticals and other key companies, straight to your email.

About Armata Pharmaceuticals

Armata Pharmaceuticals (NYSEAMERICAN:ARMP), a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

View Armata Pharmaceuticals Profile

More Earnings Resources from MarketBeat